Cerebrolysin in mild-to-moderate Alzheimer's disease: A meta-analysis of randomized controlled clinical trials

Dementia and Geriatric Cognitive Disorders

Volumn 39, Issue 5-6, 2015, Pages 332-347

  Gauthier, Serge ^a   Proanõ, Jefferson Voltaire ^b   Jia, Jianping ^c   Froelich, Lutz ^d   Vester, Johannes Christophe ^e   Doppler, Edith ^f  

^a MCGILL UNIVERSITY   (Canada)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e Department of Biometry and Clinical Research ^*  (Germany)

^f EVER Neuro Pharma GmbH   (Australia)

Author keywords

Brain; Cerebrolysin; Drug therapy; Geriatrics; Mental disorders; Mild to moderate Alzheimer's disease; Nervous system; Neurology; Pharmacology; Randomized controlled clinical trials; Therapeutics

Indexed keywords

CEREBROLYSIN; PLACEBO; AMINO ACID; NOOTROPIC AGENT;

ALZHEIMER DISEASE; COGNITION; DISEASE SEVERITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERHIDROSIS; INCIDENCE; META ANALYSIS; PATIENT CODING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; VERTIGO; DRUG EFFECTS; TREATMENT OUTCOME;

ALZHEIMER DISEASE; AMINO ACIDS; COGNITION; HUMANS; NOOTROPIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84926149110     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000377672     Document Type: Review

References (46)

1. Álvarez XA, Fuentes P: Cerebrolysin in Alzheimer's disease. Drugs Today (Barc) 2011; 47: 487-513.
2. Plosker GL, Gauthier S: Spotlight on Cerebrolysin in dementia. CNS Drugs 2010; 24: 263-266.
3. Young W: Cerebrolysin review. Originally posted April 1, 2006 (minor revisions February 10, 2009). https://wiseyoung.wordpress.com/2009/02/10/271/.
4. Fragoso YD, Dantas DC: Cerebrolysin for Alzheimer's disease. Cochrane Database Syst Rev 2002; 3:CD003801.
5. Alvarez XA, Cacabelos R, Laredo M, Couceiro V, Sampedro C, Varela M, et al: A 24-week, double-blind, placebocontrolled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol 2006; 13: 46-54.
6. Panisset M, Gauthier S, Moessler H, Windisch M: Cerebrolysin in Alzheimer's disease: a randomized, doubleblind, placebo-controlled trial with a neurotrophic agent. J Neural Transm 2002; 109: 1089-1104.
7. Ruether E, Husmann R, Kinzler E, Diabl E, Klingler D, Spatt J, et al: A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease. Int Clin Psychopharmacol 2001; 16: 253-263.
8. Riley RD, Lambert PC, Abo-Zaid G: Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 2010; 340:c221.
9. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-1364.
10. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, et al: Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11: 13-21.
11. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state'. A practical method for grading the state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
12. Oswald WD, Fleischmann UM: Das Nürnberger-Alters-Inventar NAI. Göttingen, Hogrefe, 1986.
13. Knopman DS, Knap MJ, Gracon SI, Davis CS: The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 1994; 44: 2315-2321.
14. Guy W: 028 CGI: Clinical global impressions; in Guy W (ed): ECDEU Assessment Manual for Psychopharmacology, Revised. National Institute of Mental Health, Rockville, 1976, pp 217-222.
15. Ruether E, Ritter R, Apecechea M, Freytag S, Windisch M: Efficacy of the peptidergic nootropic drug Cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry 1994; 27: 32-40.
16. Bae CY, Cho CY, Cho K, Hoon Oh B, Choi KG, Lee HS, et al: A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease. J Am Geriatr Soc 2000; 48: 1566-1571.
17. Xiao SF, Yan HQ, Yao PF; Cerebrolysin Study Group: Efficacy of FPF 1070 (Cerebrolysin) in patients with Alzheimer's disease. Clin Drug Investig 2000; 19: 43-53.
18. Birks JS, Harvey R: Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2003; 3:CD001190.
19. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. (updated March 2011). The Cochrane Collaboration, 2011.
20. IQWIG, Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen: Cholinesterasehemmer bei Alzheimer Demenz. Abschlussbericht A05-19A. IQWIG, Köln, 2007.
21. Katz R: FDA: evidentiary standards for drug development and approval. NeuroRx 2004; 1: 307-316.
22. Wei LJ, Lachin JM: Two-sample asymptotically distribution-free tests for incomplete multivariate observations. J Am Stat Assoc 1984; 79: 653-661.
23. Lachin JM: Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations. Stat Med 1992; 11: 1151-1170.
24. Dmitrienko A, Tamhane AC, Bretz F (eds): Multiple Testing Problems in Pharmaceutical Statistics. Boca Raton, Chapman and Hall/CRC, 2010.
25. Laupacis A, Sackett DL, Roberts RS: An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318: 1728-1733.
26. Cook RJ, Sackett DL: The number needed to treat: a clinically useful measure of effect. BMJ 1995; 310: 452-454.
27. Altman DG: Confidence intervals for the number needed to treat. BMJ 1998; 317: 1309-1312.
28. Guyatt GH, Juniper EF, Walter SD, Griffith LE, Goldstein RS: Interpreting treatment effects in randomised trials. BMJ 1998; 316: 690-693.
29. Walter SD: Number needed to treat (NNT): estimation of a measure of clinical benefit. Stat Med 2001; 20: 3947-3962.
30. Altman DG, Andersen PK: Calculating the number needed to treat where the outcome is time to an event. BMJ 1999; 319: 1492-1495.
31. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al: The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134: 663-694.
32. Schulz KF, Altman DG, Moher D; CONSORT Group: CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med 2010; 8: 18.
33. Gail M, Simon R: Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 1985; 41: 361-372.
34. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
35. Chang B, Lowenstein D: Report of the Quality Standards Subcommittee of the American Academy of Neurology, Appendix I: Definitions for classification of evidence. Neurology 2003; 60: 10-16.
36. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339:b2700.
37. Colditz GA, Miller JN, Mosteller F: Measuring gain in the evaluation of medical technology. The probability of a better outcome. Int J Technol Assess Health Care 1988; 4: 637-642.
38. Lachin JM: Biostatistical Methods: The Assessment of Relative Risks. New York, John Wiley and Sons, 2000.
39. Birks J, Grimley Evans J, Iakovidou V, et al: Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2009; 2:CD001191.
40. Loy C, Schneider L: Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 2006; 1:CD001747.
41. Areosa SA, Sherriff F: Memantine for dementia. Cochrane Database Syst Rev 2003; 3:CD0033154.
42. Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM: Meta-analysis of six-month memantine trials in Alzheimer's disease. Alzheimers Dement 2007; 3: 7-17.
43. Kraemer HC, Morgan GA, Leech NL, Gliner JA, Vaske JJ, Harmon RJ: Measures of clinical significance. J Am Acad Child Adolesc Psychiatry 2003; 42: 1524-1529.
44. Wei ZH, He QB, Wang H, Su BH, Chen HZ: Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease. J Neural Transm 2007; 114: 629-634.
45. Birks J, Harvey RJ: Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2006; 1:CD001190.
46. McShane R, Areosa SA, Minakaran N: Memantine for dementia. Cochrane Database Syst Rev 2006; 2:CD003154.